ZURICH, April 21 (Reuters) - Actelion Ltd, Europe's biggest biotech firm, raised its full-year guidance on Tuesday after strong sales of its new heart and lung drug helped its first-quarter earnings exceed analysts' estimates.
The Swiss drugmaker has a dominant position in treatments for pulmonary arterial hypertension (PAH) and is banking on its new drug for the condition, Opsumit, to help cut its dependence on its original blockbuster Tracleer, which loses patent protection this year.
12:02 Bank of America tops earnings forecast, predicts 'significant increase' in net interest income20
05:09 Sterling slides to 3-month lows on 'hard Brexit' fears12
01:03 Sterling slides to three-month lows on 'hard Brexit' fears11
06:50 Pittsburgh Pirates avoid arbitration with Gerrit Cole, 4 others16